Artelo Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Artelo Biosciences, Inc. scores 4/10 on the AskCyborg Cyborg Score (Weak). High-risk clinical-stage play on endocannabinoid and lipid-signaling biology; execution risk outweighs pipeline optionality for most investors. Artelo is a pre-revenue clinical-stage biotech with early-phase programs and limited near-term catalysts. Stock has undergone a 1-for-9 reverse split (August 2026), indicating prior liquidity stress.
What is Artelo Biosciences, Inc.'s industry? Artelo Biosciences, Inc. (artelobio.com) operates in Biotechnology. AskCyborg classifies Artelo Biosciences, Inc. under Biotechnology in its company registry.
Artelo Biosciences is a clinical stage biopharmaceutical company that develops and commercializes therapeutics targeting lipid-signaling pathways in the United States. The company is advancing a portfolio of broadly a...
Cyborg Score thesis
High-risk clinical-stage play on endocannabinoid and lipid-signaling biology; execution risk outweighs pipeline optionality for...
Read the full analyst-debate transcript →Get the Latest Artelo Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeArtelo Biosciences, Inc. Overview
Pro stress-test →Artelo Biosciences is a clinical stage biopharmaceutical company that develops and commercializes therapeutics targeting lipid-signaling pathways in the United States. The company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.
Strategic Profile
Pro stress-test →Artelo's pipeline includes ART27.13 (synthetic dual cannabinoid agonist in Phase 1b/2a for cancer-related anorexia), ART12.11 (cannabidiol-tetramethylpyrazine cocrystal for anxiety, depression, PTSD, epilepsy, and insomnia), and ART26.12 (FABP5 inhibitor for neuropathy and cancer-related conditions). The company positions itself at the intersection of oncology supportive care and CNS conditions with lipid-pathway modulation as its scientific differentiator.
Competitive Landscape
Pro stress-test →Artelo competes in clinical-stage cannabinoid-derived therapeutics and lipid-signaling modulators against companies pursuing similar endocannabinoid or fatty-acid pathway targets. Direct competitors are limited at early clinical stage, though the company faces broader competition from established oncology supportive care players and mood/anxiety developers. Clinical-stage biotech peers include companies with CBD/cannabinoid programs and FABP inhibitor platforms, though few are as advanced in human trials.
Industry Context
Artelo Biosciences, Inc. operates in Biotechnology.
Key facts
Founded: 2011 · Headquarters: Solana Beach, California, US · Revenue: Estimated $0 (pre-revenue clinical-stage)